2929 7th Street
Suite 105
Berkeley, CA 94710
United States
510 982 6030
https://cariboubio.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 158
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. Rachel E. Haurwitz Ph.D. | Co-Founder, CEO, President & Director | 979.08k | N/D | 1986 |
Dr. Steven B. Kanner Ph.D. | Chief Scientific Officer | 669.31k | N/D | 1960 |
Ms. Barbara G. McClung Esq., J.D. | Chief Legal Officer & Corporate Secretary | 669.31k | N/D | 1955 |
Mr. Jason V. O'Byrne M.B.A. | CFO & Principal Accounting Officer | 586.36k | N/D | 1969 |
Mr. Daniel Poon | Vice President of Operations & Information Technology | N/D | N/D | N/D |
Mr. Timothy P. Kelly M.B.A. | Chief Technology Officer | N/D | N/D | 1969 |
Ms. Amy Figueroa C.F.A. | Vice President of Investor Relations & Corporate Communications | N/D | N/D | N/D |
Ms. Reigin Zawadzki | Chief People Officer | N/D | N/D | N/D |
Ms. Ruhi A. Khan M.B.A. | Chief Business Officer | 573.9k | N/D | 1975 |
Mr. Ryan Fischesser | Vice President of Finance & Controller | N/D | N/D | N/D |
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
La calificación ISS Governance QuickScore de Caribou Biosciences, Inc. a partir del 1 de mayo de 2024 es 6. Las puntuaciones principales son Auditoría: 3; Junta: 5; Derechos del accionista: 8; Compensación: 8.